Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 2
2019 2
2020 1
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases. Joly P, et al. Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22. Lancet. 2017. PMID: 28342637 Clinical Trial.
Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; French Study Group on Autoimmune Bullous Skin Diseases; Autoimmune Bullous Skin Disease Task Force of the European Academy of Dermatology and Venereology. Hébert V, et al. J Invest Dermatol. 2019 Jan;139(1):31-37. doi: 10.1016/j.jid.2018.04.042. Epub 2018 Oct 6. J Invest Dermatol. 2019. PMID: 30301637 Free article. Review.
Efficacy and safety of anti-COVID-19 vaccination in patients with autoimmune blistering diseases: A French national study.
Ou S, Tancrède-Bohin E, Alexandre M, Ingen-Housz-Oro S, Castel M, Debarbieux S, Duvert-Lehembre S, Konstantinou MP, Abasq C, Berthin C, Couzan C, Lepelletier C, Jelti L, Bouteiller J, Calugareanu A, Véron M, Caux F, Joly P, Thomas B, Viguier M; French Study Group on Autoimmune Bullous Skin Diseases. Ou S, et al. J Am Acad Dermatol. 2024 Jan;90(1):204-208. doi: 10.1016/j.jaad.2023.08.101. Epub 2023 Sep 26. J Am Acad Dermatol. 2024. PMID: 37769901 No abstract available.
Updated French guidelines for the therapeutic management of bullous pemphigoid.
Castel M, Alexandre M, Jelti L, Pham-Ledard A, Viguier M, Bédane C, Tancrède-Bohin E, Musette P, Carvalho P, Cordel N, Caux F, Joly P; French Study Group on Autoimmune Bullous Skin Diseases. Castel M, et al. Ann Dermatol Venereol. 2022 Jun;149(2):81-91. doi: 10.1016/j.annder.2021.08.005. Epub 2021 Oct 23. Ann Dermatol Venereol. 2022. PMID: 34702559 No abstract available.
International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg-1 per day starting dose of oral corticosteroids to treat bullous pemphigoid.
Hébert V, Bastos S, Drenovska K, Meijer J, Ingen-Housz-Oro S, Bedane C, Lunardon L, Debarbieux S, Jedlickova H, Caux F, Chaby G, D'Incan M, Feliciani C, Boulard C, Schumacher N, Schmidt E, Roussel A, Richard MA, Gottlieb J, Ferranti V, Guérin O, Bénichou J, Joly P; French study group on autoimmune bullous skin diseases, and the autoimmune bullous skin disease task force of the European Academy of Dermatology and Venereology. Hébert V, et al. Br J Dermatol. 2021 Dec;185(6):1232-1239. doi: 10.1111/bjd.20593. Epub 2021 Sep 2. Br J Dermatol. 2021. PMID: 34173243
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis.
Cordel N, Flament J, Jouen F, Seta V, Tancrède-Bohin E, Dahan CP, Konstantinou MP, Dereure O, Quéreux G, Prost C, Bedane C, Debarbieux S, Lacour JP, Dompmartin A, Wierzbicka-Hainaut E, Villada IB, Oro SIH, Vabres P, Richard MA, Delaporte E, Pham-Ledard A, Leccia MT, Litrowski N, Michel C, Lagrange B, D'Incan M, Abasq C, Duvert-Lehembre S, Dupuy A, Alcaraz I, Breton-Guitarian AL, Lombart F, Estève E, Machet L, Del Giudice P, Fenot M, Belmondo T, Morin F, Guérin O, Benichou J, Tressières B, Joly P; French study Group on autoimmune bullous skin diseases. Cordel N, et al. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1207-1214. doi: 10.1111/jdv.18973. Epub 2023 Mar 6. J Eur Acad Dermatol Venereol. 2023. PMID: 36802102
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
Mignard C, Maho-Vaillant M, Golinski ML, Balayé P, Prost-Squarcioni C, Houivet E, Calbo SB, Labeille B, Picard-Dahan C, Konstantinou MP, Chaby G, Richard MA, Bouaziz JD, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V; French Study Group on Autoimmune Bullous Skin Diseases. Mignard C, et al. JAMA Dermatol. 2020 May 1;156(5):545-552. doi: 10.1001/jamadermatol.2020.0290. JAMA Dermatol. 2020. PMID: 32186656 Free PMC article. Clinical Trial.
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.
Plaquevent M, Tétart F, Fardet L, Ingen-Housz-Oro S, Valeyrie-Allanore L, Bernard P, Hebert V, Roussel A, Avenel-Audran M, Chaby G, D'Incan M, Ferrier-Le-Bouedec MC, Duvert-Lehembre S, Picard-Dahan C, Jeudy G, Collet E, Labeille B, Morice C, Richard MA, Bourgault-Villada I, Litrowski N, Bara C, Mahe E, Prost-Squarcioni C, Alexandre M, Quereux G, Bernier C, Soria A, Thomas-Beaulieu D, Pauwels C, Dereure O, Benichou J, Joly P; French Investigators for Skin Adverse Reaction to Drugs; French Study Group on Autoimmune Bullous Skin Diseases. Plaquevent M, et al. J Invest Dermatol. 2019 Apr;139(4):835-841. doi: 10.1016/j.jid.2018.10.045. Epub 2018 Dec 10. J Invest Dermatol. 2019. PMID: 30543900 Free article.